IMUNON INC (NASDAQ: IMNN)

Introduction

IMUNON INC is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey. The company develops DNA-based immunotherapies and nucleic acid vaccines aimed at addressing various diseases, including cancer and infectious pathogens.

Corporate Structure

• Headquarters: Lawrenceville, New Jersey
• Employees: 11–50 (LinkedIn)
• Leadership Experience: Over 50 combined years in research, innovation, and capital management at biotechnology and pharmaceutical companies
• Platforms:
  • TheraPlas® for cancer immunotherapy
  • PLACCINE® for nucleic acid vaccines

Development Pipeline and Collaborations

• IMNN-201 (FixPlas platform): Pre-clinical melanoma vaccine targeting the Trp2 tumor-associated antigen
• IP-Y (IndiPlas platform): Pre-clinical personalized neoepitope cancer vaccines
• Technology Evaluation with Acuitas Therapeutics (Nov 10, 2022): Evaluating PLACCINE plasmid DNA with lipid nanoparticle delivery systems

Recent Developments and News

May 22, 2025 – Registration Withdrawal Request

IMUNON filed a Form RW to withdraw Registration Statement No. 333-286403, originally filed on April 4, 2025, for a proposed initial public offering. No securities were sold, and the fees paid will be credited against future SEC filings.

May 20, 2025 – Form 8-K (Item 3.01)

A current report under Item 3.01 was filed, indicating an electronic filing matter. No material changes to financial statements were disclosed.

May 16, 2025 – Phase 1 PlaCCINE Data Announcement

IMUNON announced results from its first Phase 1 proof-of-concept trial of the PlaCCINE DNA vaccine, focusing on immunogenicity, durability, and safety. The results may support future partnerships for advancing COVID-19 and variant-targeted vaccines.

May 12, 2025 – ASCO Annual Meeting Preview

IMUNON will present data from the Phase 2 OVATION 2 study concerning its TheraPlas® ovarian cancer therapy at the ASCO Annual Meeting, scheduled for May 30 to June 3 in Chicago. The findings will center on local IL-12 expression in advanced ovarian cancer.

April 25–30, 2025 – AACR Annual Meeting Participation

The company attended the American Association for Cancer Research meeting, focusing on advances in immuno-oncology and engaging with academic and industry researchers.

Financial and Strategic Analysis

Metric	Value
Share Price (May 23, 2025)	$1.16
24-Hour Change	+179.18%
Trading Volume (May 23, 2025)	49,692,620 shares
52-Week Range	$0.37 – $3.65
Market Capitalization	$6.08 million
Trailing EPS (TTM)	-$1.38
Net Loss (TTM)	-$17.79 million
Total Cash (MRQ)	$2.87 million
Total Debt/Equity (MRQ)	223.01%
Beta (5Y Monthly)	1.75

• Liquidity & Leverage: Cash reserves are limited; the debt-to-equity ratio is above 200%, indicating a reliance on external financing.
• Profitability: The company reported no revenues, and net losses are attributed to research and development expenditures.
• Volatility: The wide 52-week price range and high trading volumes indicate speculative interest.
• Strategic Funding: Withdrawal of the S-1 registration may reflect a reassessment of the capital-raising strategy, including possible private financings or adjustments to public offering plans.

Market Position and Industry Context

• Competitive Edge: Proprietary DNA-based platforms that do not utilize viral vectors or devices may provide advantages in stability and manufacturing.
• Collaborations: The partnership with Acuitas Therapeutics focuses on lipid nanoparticle delivery, relevant to mRNA vaccine applications (e.g., COMIRNATY®).
• Target Markets:
  • Oncology: Aiming to address unmet treatment needs in ovarian cancer and melanoma via innovative immunotherapies
  • Infectious Diseases: Adaptable vaccine technology to accommodate emerging pathogens
• Industry Trends: There is growing investor interest in nucleic acid therapies and personalized oncology; regulatory frameworks for DNA vaccines are still developing compared to mRNA technologies.

tl;dr

• On May 22, 2025, IMUNON withdrew its S-1 registration without selling shares, with fees preserved for future filings.
• The company revealed data from the Phase 1 PlaCCINE vaccine trial on May 16, 2025, demonstrating safety and immunogenicity, and plans to present Phase 2 OVATION 2 ovarian cancer data at ASCO (May 30–June 3, 2025).
• Share price stood at $1.16 on May 23, 2025; market capitalization is $6.08 million while cash balance is $2.87 million, and the debt-to-equity ratio is 223%.
• The strategic focus continues on advancing two pre-clinical candidates and seeking partnerships to extend its DNA-based therapeutic platforms.